Overall fitted lines' between-trial discrepancies were evaluated.
In absolute numbers, mean force differences were below 6% for all sampling areas, with UPN having the largest between-trial discrepancies (within-day: AN ≤ 1%, UPN ≤ 3%, LPN ≤ 4%; between-day: AN ≤ 3%, UPN ≤ 6%, LPN ≤ 6%).
Although a certain degree of judgment was inevitable in categorising trials, discrepancies between independent assessors were small and easily resolved through discussion, with no material effect on the overall findings.
For seven trials, discrepancies between the planned sample size registered in http://ClinicalTrials.gov and the number of patients randomised based on the published reports were identified without any apparent explanation.
Overall EMG-force relationships displayed a maximum 6% between-trial discrepancy, with the rectilinear model being more similar between trials than curvilinear models across most of the contraction range (Fig. 4).
Overall EMG-force relationships displayed a maximum 6% between-trial discrepancy and over 20% of maximal force, and mean ICC was above 0.79 within day and 0.27 0.61 between days across areas.
Two independent reviewers extracted information from each trial, with discrepancies resolved by discussion with a third evaluator.
111, 112 Several microbicide clinical trials based on the successful in vitro anti-HIV efficacy of the microbicide candidates, however, have failed to demonstrate in vivo efficacy, presenting (except the CAPRISA 004 trial) the discrepancies between the in vitro and in vivo data.
The mechanism is unknown but should be explored in the design of future trials because in the five trials without discrepancies the effect of bone marrow stem cell therapy on ejection fraction is zero.
We investigate explanations for inconsistent results across trials and discrepancies between evidence from RCTs and other research data.
The percentage of trials with discrepancies between the protocol and the publication will be scored.
